Skip to main content
. 2016 Jun 18;7(30):47376–47386. doi: 10.18632/oncotarget.10156

Figure 3. BMI1P1 expression offers a powerful diagnostic tool in identification of AML patients.

Figure 3

(A) All patients; (B) non-M3-AML; (C) CN-AML. ROC analysis showed that the area under the curve (AUC) of BMI1P1 was 0.895 (P < 0.001), 0.906 (P < 0.001) and 0,886 (P < 0.001) in whole AML, non-M3-AML and CN-AML, respectively.